Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Jan Van Meerbeeck (Belgium). Therapeutic strategy for ALK/ROS driven NSCLC. New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine

Member's Comments

No comment yet.

Related content which might interest you: Therapeutic strategy for EGFR driven NSCLC Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 Treatment landscape in oncogene driven advanced NSCLC Source: ERS Skills course: Multi-disciplinary care in thoracic oncology Year: 2019 Clinical impact of immunotherapy in NSCLC treatment landscape Source: ERS Skills course: Multi-disciplinary care in thoracic oncology Year: 2019 Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer Source: Eur Respir J 2013; 42: 1119-1133 Year: 2013 Therapeutic options targeting angiogenesis in nonsmall cell lung cancer Source: Eur Respir Rev 2014; 23: 79-91 Year: 2014 Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm Source: Eur Respir J, 55 (2) 1901907; 10.1183/13993003.01907-2019 Year: 2020 Successful targeted therapy of advanced lung cancer Source: Annual Congress 2013 –Grand Round on diagnostic and therapeutic challenges in thoracic oncology: an interactive session Year: 2013 Multimodal therapeutic approach for locally advanced NSCLC in everyday practice Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018 Combined modality treatment for NSCLC Source: Annual Congress 2007 - PG7 - Thoracic oncology: nonsmall cell lung cancer Year: 2007 NSCLC management Source: ERS Course 2019 - Summer school of adult respiratory medicine Year: 2019 NSCLC management Source: ERS Skills Course 2017 - Summer school of adult respiratory medicine Year: 2017 NSCLC management Source: ERS Course 2018 - Summer school of adult respiratory medicine Year: 2018 NSCLC management Source: ERS Skills Course 2016 Year: 2016 Targeted therapies: detrimental treatment for nonsmall cell lung cancer without driver mutations Source: Eur Respir J 2015; 46: 19-21 Year: 2015 Novel approaches in metastasised non-small cell lung cancer with a special focus on modern systemic therapies Source: International Congress 2019 – State of the art session: Thoracic oncology Year: 2019 New treatment concepts in stage IV non-small cell lung cancer: personalised multidisciplinary approaches Source: Virtual Congress 2021 – Thoracic oncology Year: 2021 Targeting Tryptophan metabolism pathway as a therapeutic strategy for non-small cell lung cancer Source: International Congress 2019 – Biology of lung cancer Year: 2019 New and anticipated therapeutic developments in management of non-small-cell lung cancer Source: Annual Congress 2013 –ERS/The Lancet/The Lancet Respiratory Medicine joint Lunchtime session on lung cancer Year: 2013 Radiation therapy for augmenting the efficacy of immunotherapy in advanced non-small cell lung cancer: a case-controlled study Source: ERJ Open Res, 6 (1) 00189-2019; 10.1183/23120541.00189-2019 Year: 2020 First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology Source: Eur Respir Rev 2014; 23: 92-105 Year: 2014